risedronate

(redirected from Atelvia)
Also found in: Medical.

ri·sed·ro·nate

(rĭ-sĕd′rə-nāt′)

A bisphosphonate drug, C₇H₁₁NO₇P₂, that inhibits bone resorption and is used in the form of its sodium salt to treat and prevent osteoporosis in postmenopausal women.

[Perhaps (py)ri(dine) + -se-, origin unknown + (hy)dr(oxy) + (bisphosph)onate.]

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

Translations

risedronate, risedronate sodium

(USAN), risedronic acid (INN) n risedronato, risedronato sódico, ácido risedrónico (INN)

References in periodicals archive ?

Norethindrone acetate/ethinyl estradiol, the generic version of Lo Loestrin Fe; and risedronate sodium, the generic version of Atelvia, are awaiting regulatory approvals.

Amneal Pharmaceuticals LLC to buy four generic products from Actavis Inc

(12) A delayed release form of risedronate (Atelvia) has been approved for the treatment of postmenopausal osteoporosis.

Current treatment approaches to osteoporosis--2013

Other bisphosphonate drugs that were not tested in the study include risedronate (Actonel, Atelvia), alendronate (Fosamax), and iban-dronate (Boniva).

Osteoporosis drugs slow bone loss, but do not aid in bone formation: bisphosphonates, such as Zometa, inhibit the breakdown of bone; to build bone, it's essential to eat a calcium-rich diet and exercise regularly

A new delayed-release formulation of risedronate (Atelvia) was approved by the FDA in late 2010 and made available for prescribing earlier this year.

New delayed-release bisphosphonate can be taken with food

The drugs include oral forms--alendronate (Fosamax) and risedronate (Actonel, Atelvia)--and injectable forms--ibandronate (Boniva) and zoledronic acid (Reclast).

Benefits of osteoporosis drugs outweigh risks: bisphosphonates are still beneficial, but taking time off of them after long-term use may alleviate fracture concerns

These include Fosamax, Fosamax Plus D, Actonel, Actonel with Calcium, Boniva, Atelvia, and Reclast, and their generics.

Stories of importance in 2010

The drugs affected are Actonel; Actonel Plus Calcium; Atelvia; Boniva; Fosamax; Fosamax Plus D; and Reclast, as well as their generic offspring.

Osteoporosis drugs' "broken" promise

The products affected are those approved for osteoporosis indications, such as alendronate (Fosamax), alendronate and cholecalciferol (Fosamax Plus D), risedronate sodium (Actonel), risedronate sodium with calcium carbonate (Actonel with Calcium), ibandronate sodium (Boniva), risedronate sodium (Atelvia), pamidronate injection (Aredia), and zoledronic acid injection (Reclast), as well as generic formulations of those drugs.